Zai Lab
ZLAB
191 hedge funds and large institutions have $7.27B invested in Zai Lab in 2020 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 92 increasing their positions, 42 reducing their positions, and 20 closing their positions.
119% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 42
105% more call options, than puts
Call options by funds: $5.74M | Put options by funds: $2.8M
75% more capital invested
Capital invested by funds: $4.15B → $7.27B (+$3.12B)
75% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 20
9% more funds holding
Funds holding: 176 → 191 (+15)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
5.99% less ownership
Funds ownership: 66.97% → 60.98% (-6%)
Top Buyers
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$134M |
| 2 |
SCM
Segantii Capital Management
Hong Kong
|
-$61.2M |
| 3 |
Goldman Sachs
New York
|
-$60.1M |
| 4 |
ZAM
Zeal Asset Management
Central,
Hong Kong
|
-$23.2M |
| 5 |
JP Morgan Chase
New York
|
-$15.4M |
ZLAB Hedge Fund Activity: Q4 2020 in Review
191 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Zai Lab (ZLAB) for Q4 2020, worth a combined $7.27B — up 75% from $4.15B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ZLAB positions and 20 closed out — a net gain of 15 holders — while 92 added to existing stakes and 42 trimmed.
The largest buyer was Brilliance Asset Management, adding an estimated $240M. The largest seller was Fidelity Investments, cutting an estimated $134M.
- 191 institutional investors held Zai Lab (ZLAB) as of Q4 2020, up from 176 in Q3 2020.
- Funds reported $7.27B of Zai Lab stock for Q4 2020, up 75% quarter-over-quarter.
- 35 funds opened new Zai Lab positions in Q4 2020 and 20 closed out, a net change of +15 holders.
- The largest Zai Lab buyer in Q4 2020 was Brilliance Asset Management, an estimated $240M added.
- The largest Zai Lab seller in Q4 2020 was Fidelity Investments, an estimated $134M sold.
Based on aggregated 13F filings for Q4 2020.